The global acne therapeutics market size was estimated to be USD 8.34 billion in 2023 and is expected to reach at USD 15.8 billion by 2033 with a CAGR of 5.98% during the forecast period 2023-2033. Increasing prevalence of acne vulgaris, rising patient inflow to dermatology clinics, rise in sedentary lifestyles, growing disposable income of consumers, surge in awareness about acne treatments, increasing demand of aesthetics & non-invasive procedures, rising demand for a brighter and glowing skin appearance, surge in unhealthy lifestyle, and growing launch of novel products for the treatment of acne vulgaris are some of the key factors propelling the market growth.
Growing launch of novel products for the treatment of acne vulgaris is predicted to boost the market growth during the forecast period. For instance, in June 2020, Bausch Health Co. has launched ARAZLO lotion, intended for patients aged nine and above experiencing skin eruptions categorized as acne vulgaris.
By Treatment, Therapeutics was the highest revenue-grossing segment in the global acne therapeutics market in 2022 owing to growing demand for retinoids creams & gels, increasing research and development activities, rising launch of novel & generic products of retinoids. For instance, in February 2022, Stryke Club has unveiled their Knockout Adapalene Gel, an acne treatment that incorporates retinoids, effectively preventing the occurrence of pimples, blackheads, whiteheads, and clogged pores. This prescription-strength retinoid acne treatment is FDA-approved and is now available for purchase without a prescription. Additionally, Devices is predicted to grow at fastest CAGR during the forecast period owing to the surge in demand for non-invasive procedures and increasing technological advancements.
By Route of Administration, Topical was the highest revenue-grossing segment in the global acne therapeutics market in 2022 owing to increasing demand of cream & gel-based products, rising adoption of non-invasive procedures, and surge in introduction of innovative products. For instance, in November 2021, Sun Pharmaceuticals has introduced Winlevi (Clascoterone cream 1%), a groundbreaking topical treatment for acne vulgaris, in the United States. Additionally, Oral is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of acne and increasing demand for over-the-counter (OTC) medicines.
By End User, Medspas was the highest revenue-grossing segment in the global acne therapeutics market in 2022 owing to growing demand for chemical peels & scrubs for the treatment of acne, rising concerns regarding acne, and presence of qualified medical professionals. Additionally, Dermatology clinics is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of acne vulgaris, rising demand of creams & lotions for various skin conditions, and growing launch of new products. For instance, in March 2022, At the American Academy of Dermatology Annual Meeting, Galderma unveiled TWYNEO Cream for the treatment of facial acne, which has now been launched in the United States. This product will be commercially accessible in the spring.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising awareness regarding acne treatment among the population, increasing presence of leading market players, growing prevalence of acne, surge in product launches, rising development of novel acne therapies, growing mergers & acquisitions within market players, and increasing product approvals in acne treatment by regulatory bodies. For instance, in August 2022, HealthCanada has granted clearance to Cutera for their product AviClear, which is approved for treating varying degrees of acne and acne scars, including mild, moderate, and severe cases. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing usage of retinoid creams, lotions & gels for anti-aging, rising concerns regarding acne & other skin problems, and growing launch of new products. For instance, in September 2021, Japanese celebrity Becky has launched her own skincare brand, NaturaLUNA, which is directly available to consumers. To facilitate this, she has utilized the comprehensive D2C platform provided by AnyMind Group, encompassing AnyFactory, AnyShop, and AnyLogi.
Growing launch of novel products for the treatment of acne vulgaris is predicted to boost the market growth during the forecast period. For instance, in June 2020, Bausch Health Co. has launched ARAZLO lotion, intended for patients aged nine and above experiencing skin eruptions categorized as acne vulgaris.
By Treatment, Therapeutics was the highest revenue-grossing segment in the global acne therapeutics market in 2022 owing to growing demand for retinoids creams & gels, increasing research and development activities, rising launch of novel & generic products of retinoids. For instance, in February 2022, Stryke Club has unveiled their Knockout Adapalene Gel, an acne treatment that incorporates retinoids, effectively preventing the occurrence of pimples, blackheads, whiteheads, and clogged pores. This prescription-strength retinoid acne treatment is FDA-approved and is now available for purchase without a prescription. Additionally, Devices is predicted to grow at fastest CAGR during the forecast period owing to the surge in demand for non-invasive procedures and increasing technological advancements.
By Route of Administration, Topical was the highest revenue-grossing segment in the global acne therapeutics market in 2022 owing to increasing demand of cream & gel-based products, rising adoption of non-invasive procedures, and surge in introduction of innovative products. For instance, in November 2021, Sun Pharmaceuticals has introduced Winlevi (Clascoterone cream 1%), a groundbreaking topical treatment for acne vulgaris, in the United States. Additionally, Oral is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of acne and increasing demand for over-the-counter (OTC) medicines.
By End User, Medspas was the highest revenue-grossing segment in the global acne therapeutics market in 2022 owing to growing demand for chemical peels & scrubs for the treatment of acne, rising concerns regarding acne, and presence of qualified medical professionals. Additionally, Dermatology clinics is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of acne vulgaris, rising demand of creams & lotions for various skin conditions, and growing launch of new products. For instance, in March 2022, At the American Academy of Dermatology Annual Meeting, Galderma unveiled TWYNEO Cream for the treatment of facial acne, which has now been launched in the United States. This product will be commercially accessible in the spring.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising awareness regarding acne treatment among the population, increasing presence of leading market players, growing prevalence of acne, surge in product launches, rising development of novel acne therapies, growing mergers & acquisitions within market players, and increasing product approvals in acne treatment by regulatory bodies. For instance, in August 2022, HealthCanada has granted clearance to Cutera for their product AviClear, which is approved for treating varying degrees of acne and acne scars, including mild, moderate, and severe cases. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing usage of retinoid creams, lotions & gels for anti-aging, rising concerns regarding acne & other skin problems, and growing launch of new products. For instance, in September 2021, Japanese celebrity Becky has launched her own skincare brand, NaturaLUNA, which is directly available to consumers. To facilitate this, she has utilized the comprehensive D2C platform provided by AnyMind Group, encompassing AnyFactory, AnyShop, and AnyLogi.
Segmentation: Acne Therapeutics Market Report 2022 - 2033
Acne Therapeutics Market Analysis & Forecast by Treatment 2022 - 2033 (Revenue USD Bn)
Therapeutics
- Hormonal Agents
- Antibiotics
- Retinoid
- Chemical Peels
- Anti-inflammatory
Devices
- Radio Frequency Devices
- Laser Devices
Acne Therapeutics Market Analysis & Forecast by Route of Administration 2022 - 2033 (Revenue USD Bn)
- Topical
- Injectable
- Oral
Acne Therapeutics Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- MedSpa
- Dermatology Clinics
Acne Therapeutics Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Acne Therapeutics Market: Treatment Estimates & Trend Analysis
8. Acne Therapeutics Market: Route of Administration Estimates & Trend Analysis
9. Acne Therapeutics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Acne Therapeutics Market
12. Europe Global Acne Therapeutics Market
13. Asia Pacific Global Acne Therapeutics Market
14. Latin America Global Acne Therapeutics Market
15. MEA Global Acne Therapeutics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Abbvie Inc. (Allergan PLC)
- PHYTOMER
- Johnson & Johnson
- Jan Marini Skin Research
- L'Oréal S.A. (La Roche-Posay Laboratoire Dermatologique)
- Skin Medica
- Teva Pharmaceuticals
- Skin Better Science
- Sun Pharmaceutical Industries Inc.
- Colorescience
- Obaji
- PCA
- Perricone MD
- Sente
- Glow Biotics LLC
- Revision Skincare
- The BeautyHealth Company
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 8.34 Billion |
| Forecasted Market Value ( USD | $ 15.8 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
